
Opinion|Videos|June 21, 2024
Exploring EGFR Mutations and Prevalence in Non-Small Cell Lung Cancer
Cara Chang, PharmD, BCOP, examines the prevalence of EGFR positivity, provides an overview of clinically relevant EGFR mutations, and discusses therapeutic options for EGFR-positive mutations.
Advertisement
Episodes in this series

Now Playing
- To set the stage for EGFR+ metastatic NSCLC, what is the prevalence of EGFR positivity? What are the different EGFR mutations that are relevant to treatment decisions, and what are their respective frequencies?
- Provide a broad overview of therapy options in EGFR+ mutations, including a comparison of mechanism of action between 1st, 2nd, and 3rd generation oral TKIs as well as the bispecific antibody amivantamab.
- Discuss the dual targets of amivantamab, and the role of MET-targeted therapies in overcoming EGFR therapy resistance
- The NCCN guideline has undergone several updates regarding the management of various mutation groups. Beginning with our most prevalent mutations, EGFR Ex19del or exon 21 L858R, what are the currently recommended treatment options for initial management?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Outcomes of Older Patients on Enfortumab Vedotin for Urothelial Carcinoma
2
Single-Center Experience With Vorasidenib in Patients With Grade 3 or 4 IDH-Mutant Gliomas
3
FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence
4
McKesson ideaShare 2026: Why Automation and AI Are Reshaping the Dispensing Experience
5





















































































































